Fig. 1 · Structure

Documents & Downloads

Pioglitazone (Actos)

Cat. No. A11680 CAS 111025-46-8

PPARγ agonist

Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
hPPARγ EC50 0.93 μM
mouse PPARγ EC50 0.99 μM
hPPARδ EC50 43μM
hPPARα EC50 100μM
mouse PPARα EC50 100μM

Cellular Effect

Cell Line Activity Value Description Reference
CHO EC50 0.14 μM Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay [PMID: 20656494]
CHO EC50 0.39 μM Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay [PMID: 21377875]
COS-1 EC50 0.39 μM Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 by luciferase reporter gene assay [PMID: 21130649]
COS-7 EC50 0.2 μM Transactivation of human PPARgamma expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay [PMID: 26595749]
COS-7 EC50 0.2 μM Transactivation of GAL4-fused human PPARgamma ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay [PMID: 23130964]
COS-7 EC50 0.3 μM Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay [PMID: 21873070]
COS-7 EC50 0.3 μM Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay [PMID: 20307981]
COS-7 EC50 0.32 μM Transactivation at Gal4 fused PPARgamma LBD (unknown origin) expressed in African green monkey COS7 cells after 42 hrs by luciferase assay [PMID: 27569195]
COS-7 EC50 0.5 μM Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay [PMID: 27560282]
CV-1 EC50 580 nM Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay. [PMID: 11720854]
HEK293 EC50 0.21 μM Agonist activity at human PPARgamma expressed in HEK293 cells incubated for 18 hrs by luciferase reporter gene assay [PMID: 25333853]
HEK293 EC50 0.8 μM Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay [PMID: 23102891]
HEK293 EC50 1.1 μM Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay [PMID: 28465099]
HEK293 IC50 22 μM Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay [PMID: 28465099]
HepG2 EC50 0.57 μM Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay [PMID: 22341573]
HT-1080 IC50 > 100 μM Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay [PMID: 28395220]
MDA-MB-231 IC50 > 100 μM Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay [PMID: 28395220]
Mesenchymal stem cells EC50 0.5 μM Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay [PMID: 37077388]
Mesenchymal stem cells EC50 0.79 μM Induction of adipogenesis in differentiated human BMMSC cells assessed as fold increase in adiponectin level in presence of IDX by ELISA [PMID: 36475432]

19 records · Scroll to view more

Pioglitazone (Actos) Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Pioglitazone (Actos) from 3 published references. In vitro models include 22RV1. In vivo models include six-week-old male C57BL/6J mice.

Pioglitazone (Actos) In Vitro Studies

Pioglitazone exposure for 72 h significantly decreased cell viability in 22RV1 cells in a dose-dependent manner compared with vehicle-treated control cells. Cellular metabolic activity was assessed through redox potential using the resazurin assay. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Dose-dependent decrease in cell viability

Cell-based study · 22RV1 [1]

22RV1 cells were exposed to Pioglitazone for 72 h, with cellular metabolic activity assessed using the resazurin assay. Cell viability significantly decreased in a dose-dependent manner compared with vehicle-treated control cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cellular metabolic activity indicated by their redox potential via the resazurin assayReported result significantly decreased cell viability in a dose-dependent manner after 72 h of exposure[1]

Literature-Reported Treatment Conditions

Treatment concentration
10, 50, 100, 200, 300 µM
Exposure duration
72 h
Vehicle
0.2% DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Pioglitazone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell viability and proliferation assay (S15, S16, S17); Results > PPAR agonists inhibit cell proliferation in primary and metastatic PCa cells (S175, S176)

cellular metabolic activity indicated by their redox potential via the resazurin assay: cellular metabolic activity indicated by their redox potential via the resazurin assay; comparator: vehicle-treated control cells — Results > PPAR agonists inhibit cell proliferation in primary and metastatic PCa cells (S175, S176)

Pioglitazone (Actos) In Vivo Studies

Pioglitazone significantly reduced tumor volume in male NSG mice bearing PC3 xenografts compared with vehicle control. In male C57BL/6J mice, Pioglitazone-supplemented HFD decreased epididymal fat adipocyte size by ∼36% compared with HFD alone; data were not shown. In male C57BL/6 mice receiving CDAHFD, Pioglitazone reduced serum ALT compared with CDAHFD plus vehicle control, with a reported value of 202.9 ± 16.5 U/L. [1,2,3]

Reduced tumor volume in a mouse xenograft model

Animal study · mouse xenograft experiment of PC3 cells in male NSG mice [1]

Male NSG mice bearing PC3 xenografts received Pioglitazone at 10 mg/kg daily by oral gavage. Pioglitazone significantly reduced tumor volume compared with vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume throughout the 14 days of treatmentReported result Pioglitazone significantly reduced tumor volume after day 6 of treatment[1]

Conditions shared by the study groups

Route
oral gavage
Treatment course
daily
Vehicle
20% hydroxypropyl-beta cyclodextrin
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pioglitazone 10 mg/kgvehicle control (20 % hydroxypropyl-beta cyclodextrin) (n = 6)Pioglitazone significantly reduced tumor volume after day 6 of treatment[1]
Pioglitazone 10 mg/kg
Model: mouse xenograft experiment of PC3 cells in male NSG mice
Methods and source locations

Compound reported in the paper: Pioglitazone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Xenograft (S142, S144); Results > Pioglitazone suppresses cell migration of PCa cells and growth of metastatic PC3 xenograft tumors (S253, S255, S267)

Tumor volume throughout the 14 days of treatment: Tumor volume throughout the 14 days of treatment; comparator: vehicle control (20 % hydroxypropyl-beta cyclodextrin) (n = 6) — Results > Pioglitazone suppresses cell migration of PCa cells and growth of metastatic PC3 xenograft tumors (S255, S267)

Pioglitazone 10 mg/kg · Materials and Methods > Xenograft (S144); Results > Pioglitazone suppresses cell migration of PCa cells and growth of metastatic PC3 xenograft tumors (S255)

Decreased adipocyte size during high-fat feeding

Animal study · Six-week-old male C57BL/6J mice [2]

Male C57BL/6J mice received HFD supplemented with Pioglitazone at 10 mg · kg−1 · day−1. Treatment decreased epididymal fat adipocyte size by ∼36% compared with HFD alone; data were not shown.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
average adipocyte size in epididymal fat tissueadipocyte size decreased the adipocyte size by ∼36%[2]

Conditions shared by the study groups

Route
HFD supplemented with pioglitazone
Treatment course
for the last 5 weeks of 17-week HFD treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pioglitazone 10 mg · kg−1 · day−1HFDPioglitazone treatment decreased the adipocyte size by ∼36% (data not shown).[2]
Pioglitazone 10 mg · kg−1 · day−1
Model: Six-week-old male C57BL/6J mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Pioglitazone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESEARCH DESIGN AND METHODS > Maintenance of mice. (S4, S6, S7); RESULTS > M1 macrophage markers were increased by high-fat feeding and decreased by pioglitazone treatment, while M2 macrophage markers were not. (S34, S35, S36)

average adipocyte size in epididymal fat tissue: average adipocyte size in epididymal fat tissue; comparator: HFD — RESULTS > M1 macrophage markers were increased by high-fat feeding and decreased by pioglitazone treatment, while M2 macrophage markers were not. (S35, S36)

Pioglitazone 10 mg · kg−1 · day−1 · RESEARCH DESIGN AND METHODS > Maintenance of mice. (S7); RESULTS > M1 macrophage markers were increased by high-fat feeding and decreased by pioglitazone treatment, while M2 macrophage markers were not. (S34, S36)

Reduced serum ALT in a dietary mouse model

Animal study · Male C57BL/6 mice; n = 9/gp [3]

Male C57BL/6 mice receiving CDAHFD were treated with Pioglitazone at 30 mg/kg by oral gavage once daily. Serum ALT was reduced compared with CDAHFD plus vehicle control, with a reported value of 202.9 ± 16.5 U/L.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum ALT (U/L)Serum ALT 202.9 ± 16.5 U/L[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
treatment was continued for 12 week duration by oral gavage once daily
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pioglitazone 30 mg/kgCDAHFD‐Vehicle Controlreductions in serum ALT; 202.9 ± 16.5 U/L; **P < .01 vs CDAHFD + Vehicle Control (disease control)[3]
Pioglitazone 30 mg/kg
Model: Male C57BL/6 mice; n = 9/gp
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Pioglitazone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Animal experiments (S21, S23, S24, S26); RESULTS > Saroglitazar reverses CDAHFD‐induced NASH in C57BL/6 mice (S76); Figure 3 legend (S105); Table 1 legend (S120); Table 1 (T1.h1, T1.r2)

Serum ALT (U/L): Serum ALT (U/L); comparator: CDAHFD‐Vehicle Control — RESULTS > Saroglitazar reverses CDAHFD‐induced NASH in C57BL/6 mice (S76); Table 1 legend (S120); Table 1 (T1.h1, T1.r2)

Pioglitazone 30 mg/kg · MATERIALS AND METHODS > Animal experiments (S23, S24); RESULTS > Saroglitazar reverses CDAHFD‐induced NASH in C57BL/6 mice (S76); Table 1 legend (S120); Table 1 (T1.h1, T1.r2)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 111025-46-8
Applications PPARγ agonist
Formula C19H20N2O3S
Molecular Weight 356.4
Synonyms Actos
SMILES
CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Pioglitazone (Actos) Research References

  1. [1] Atas E, Berchtold K, Schlederer M, et al. The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer. Mol Cancer (2025). PMID: 40320521 DOI: 10.1186/s12943-025-02320-y Source material
  2. [2] Fujisaka S, Usui I, Bukhari A, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes (2009). PMID: 19690061 DOI: 10.2337/db08-1475 Source material
  3. [3] Jain MR, Giri SR, Bhoi B, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int (2018). PMID: 29164820 DOI: 10.1111/liv.13634 Source material

Added to your cart

View Cart Checkout
Loading...